37 stories
Wegovy is Novo Nordisk's branded semaglutide for chronic weight management. The injectable form launched in 2021. Oral Wegovy — a reformulated, higher-dose oral semaglutide — launched in late 2025 and early 2026, with the 1.5mg starter dose at $149/month and the 4mg dose moving from $149 to $199 effective April 15, 2026.
The most cited Wegovy data: SELECT (20% MACE reduction in non-diabetic adults with obesity), the STEP series for weight loss, and recent comparative work suggesting oral Wegovy may edge ahead of Foundayo (orforglipron) on weight loss despite Foundayo's HbA1c lead. Wegovy is on the FDA's April 30 proposal to exclude semaglutide from the 503B bulks list — the compounded-Wegovy market has been a core revenue threat for Novo.
Stories here cover pricing, head-to-head readouts, payer coverage, and the compounding economics.
The first definitive Phase 3B head-to-head trial of Lilly's tirzepatide versus Novo Nordisk's semaglutide in 750 patients with obesity over 72 weeks showed tirzepatide produced 21.6% mean weight loss vs semaglutide's 15.4%. 36.2% of tirzepatide patients achieved ≥25% weight loss vs 19.4% on semaglutide. Results published April 20 give Lilly a clear comparative data point in the GLP-1 market share battle.
April 20, 2026 is the CMS application deadline for Medicare Part D plans to participate in the BALANCE Model, which will offer Wegovy, Zepbound KwikPen, and Foundayo at $50 copay with a $245/month net price starting July 1. CMS added Foundayo to the Medicare GLP-1 Bridge on April 6 following FDA approval, extending coverage to Lilly's new oral GLP-1.
Novo Nordisk's oral Wegovy 4mg dose increased from the introductory $149/month to $199/month effective April 15, as previously announced. The 1.5mg starter dose remains at $149/month, while maintenance doses (9mg, 25mg) stay at $299/month. The price increase applies to the NovoCare self-pay channel.
The FDA granted Apotex Corp. the first-ever tentative approval for a generic semaglutide injection equivalent to Ozempic/Wegovy. Actual market entry is blocked by Novo Nordisk patents until ~2032, but the milestone proves a complex peptide injectable can meet FDA generic equivalence standards.
Novo Nordisk received accelerated FDA approval for Wegovy HD, a higher-dose injectable semaglutide offering ~21% weight loss, with aggressive discount pricing to fight Lilly's market share gains.
Three months into its launch, oral Wegovy has driven explosive prescription demand, largely attracting new patients who avoided injections. Early data suggest the pill is expanding the obesity market rather than cannibalizing injectable users.
Amazon Pharmacy expanded access to the new oral Wegovy pill with both insurance and cash-pay options, signaling a broader retail push to capitalize on surging oral GLP-1 demand.
Phase IIIb results show investigational 7.2 mg semaglutide dose produced 21% mean weight loss in adults with obesity without diabetes, with a tolerable safety profile.
WeightWatchers began offering oral Wegovy with promotional pricing. Clinical trials showed 13.6% body weight loss with oral formulation versus 14.9% injectable.
Managed Healthcare Executive compares Foundayo (orforglipron) vs oral Wegovy (semaglutide). ACHIEVE-3 trial data showed Foundayo superior on HbA1c, but oral Wegovy may edge ahead on weight loss.
In-depth comparison of Foundayo against existing GLP-1 drugs, noting 27 lbs average weight loss over 72 weeks at the highest dose. Experts hope more oral options will drive down costs and offer patients greater flexibility versus injectable regimens.
Novo Nordisk cut Ozempic prices 36% and Wegovy 48% in India as generic semaglutide from Dr Reddy's, Sun Pharma, and Zydus entered the market with prices as low as Rs 1,290/month.
Under new UK guidance, GPs can prescribe semaglutide (Wegovy) to overweight patients who have had heart attacks, strokes, or serious circulation problems, expanding its use beyond weight management.
The FDA approved once-daily oral semaglutide (Wegovy) 25 mg as the first GLP-1 pill for weight loss, offering a convenient alternative to injections with comparable weight loss to the original injection.
FDA approved oral Wegovy (semaglutide) based on OASIS 4 trial showing significant improvements in glycemic control and cardiovascular risk factors. Novo Nordisk plans full US launch from North Carolina manufacturing.
AJMC covers the oral GLP-1 era: participants on 25mg oral semaglutide saw ~16.6% weight loss when adherent, comparable to injectable outcomes. Discusses broader market implications.
Hims & Hers announced Novo Nordisk's approved GLP-1 medications including Wegovy injections/pills and Ozempic are now available through its platform at lower-than-retail rates.
Novo will reduce prices to $675/month starting January 1, 2027 — approximately 50% cut for Wegovy and 35% for Ozempic, aimed at patients on high-deductible plans.